Vaccinium para Trastornos hepáticos
Vaccinium arctostaphylos — 4 estudios científicos revisados
Moderate¿Sirve Vaccinium para trastornos hepáticos?
Uso documentado en la medicina tradicional y respaldado por investigación preliminar
Compuestos activos involucrados: Fenoles, Flavonoides, Glucosa, Polifenoles, Saponinas, Terpenos, Tirosinasa, Compuestos fenólicos
Evidencia Científica
Los siguientes estudios han investigado la relación entre Vaccinium y trastornos hepáticos:
The Potential Hepatoprotective Effect of
OBJECTIVE: MATERIALS AND METHODS: In this experimental study, male Wistar rats were randomly assigned to four groups: normal control, normal rats with VAE treatment, diabetic control, and diabetic rats with VAE treatment. Following 42 days of treatment, the impact of VAE on diabetes-induced rats was assessed by measuring various serum biochemical parameters, including insulin, free fatty acids (FFA), tumor necrosis factor-α (TNF-α), reactive oxygen species (ROS), and adiponectin levels. The activities of hepatic carbohydrate metabolic enzymes and glycogen content were determined. Additionally
PubMed: 37865880Hepatoprotective effects of Vaccinium arctostaphylos against CCl4-induced acute liver injury in rats.
BACKGROUND: This study was carried out to evaluate the antioxidant and hepatoprotective effects of Vaccinium arctostaphylos (V.a) methanolic extract on carbon tetrachloride (CCl4)-induced acute liver injury in Wistar rats. METHODS: Total phenolic and total flavonoid contents as well as antioxidant activity of V.a were determined. Extracts of V.a at doses of 200 and 400 mg/kg were administered by oral gavage to rats once per day for 7 days and then were given an intraperitoneal injection of 1 mL/kg CCl4 (1:1 in olive oil) for 3 consecutive days. Serum biochemical markers of liver injury, oxidat
PubMed: 28467312Anti-hyperglycemic effect of Vaccinium arctostaphylos in type 2 diabetic patients: a randomized controlled trial.
BACKGROUND: Type 2 diabetes mellitus is a common disease. Preliminary data indicate that Vaccinium arctostaphylos L. (Caucasian whortleberry) has a potential effect in glycemic control. Thus, the efficacy and safety of a standardized whortleberry fruit hydroalcoholic extract in the treatment of type 2 diabetic patients were studied. METHODS: This randomized double-blind placebo-controlled clinical trial consisted of 37 patients aged 40-60 years with type 2 diabetes who were resistant to conventional oral anti-hyperglycemic drugs.
PubMed: 23727759Improved lipid profile in hyperlipidemic patients taking Vaccinium arctostaphylos fruit hydroalcoholic extract: a randomized double-blind placebo-controlled clinical trial.
Dyslipidemia is a common contributory cause of cardiovascular disease. Vaccinium arctostaphylos L. (Caucasian whortleberry) fruit is rich of anthocyanins. Anthocyanins may exert cardioprotective effects by various mechanisms such as favorably modulating dyslipidemia. Therefore, in this randomized double-blind placebo-controlled clinical trial with hyperlipidemic (hypercholesterolemic and/or hypertriglyceridemic) patients aged 20-60 years, the effects of taking a standardized whortleberry fruit hydroalcoholic extract (one 350 mg capsule every 8 h for 2 months) on fasting blood levels of lipids,
PubMed: 23686894Contexto Científico
A continuación, se detallan cuatro estudios significativos que ilustran su potencial: Primero, un estudio realizado en ratas Wistar diabéticas buscaba investigar el efecto hepatoprotector del extracto de la planta (VAE) [PMID 36556444].
Seguridad y Precauciones
La seguridad del consumo de Vaccinium arctostaphylos debe abordarse con precaución debido a sus potentes efectos farmacológicos sobre el metabolismo de la glucosa y la presión arterial. En cuanto al embarazo y la lactancia, no existe evidencia clínica suficiente en humanos que garantice la seguridad del uso de extractos concentrados de esta planta en mujeres gestantes o lactantes. Dado que estudios en modelos animales sugieren efectos sobre la expresión génica y el metabolismo (como la regulación de la insulina y el transporte de glucosa), existe un riesgo teórico de interferencia con el desarrollo fetal o la transferencia de compuestos bioactivos a través de la leche materna. La falta de estudios de seguridad en humanos durante estas etapas clínicas obliga a recomendar la abstención de su uso terapéutico en estos grupos vulnerables. Para niños menores de 12 años, el uso de extractos de Vaccinium arctostaphylos no está indicado. El desarrollo fisiológico de los infantes es altamente sensible a cambios en los niveles de glucosa y hormonas; el uso de agentes con propiedades hipoglucemiantes podría provocar episodios de hipoglucemia (niveles bajos de azúcar en sangre) difíciles de manejar en pediatría.
Otras plantas estudiadas para Trastornos hepáticos
Perfil completo: Ver todos los usos y evidencia de Vaccinium →